GRAIL investors face Aug. 4, 2026 lead plaintiff deadline in securities class action

Purchasers of GRAIL, Inc. common stock between May 13, 2025 and Feb. 19, 2026 have until Aug. 4, 2026 to seek appointment as lead plaintiff in a proposed securities class action, according to law firm notices from Rosen Law Firm and Robbins Geller Rudman & Dowd LLP. The lawsuit, identified by Robbins Geller as Robbins v. Grail, Inc., No. 26-cv-05428 (N.D. Cal.), alleges GRAIL and certain current and former executive officers violated U.S. securities laws by giving investors a misleading impression about the likelihood that the NHS-Galleri trial would meet its primary endpoint. The complaint, as described in the releases, centers on statements following top-line results from the first screening round and on alleged failures to disclose detailed topline data or other information that may have indicated the three-year follow-up period was insufficient to demonstrate a statistically significant reduction in late-stage Stage III-IV cancers. Robbins Geller said GRAIL disclosed on Feb. 19, 2026 that the trial’s “primary endpoint of statistically significant Stage III-IV reduction was not observed” and that it would “probably need[] a longer follow-up time” to compare study arms adequately; the complaint says the stock then fell more than 50%. Both notices said investors do not need to serve as lead plaintiff to share in any potential recovery, and that the lead plaintiff role generally goes to the investor with the largest financial interest who also meets adequacy and typicality requirements under the Private Securities Litigation Reform Act of 1995.